Key result
In patients with severe COVID-19 pneumonia, right ventricular systolic dysfunction defined by an RV-FWLS < 21% was not associated with 30-day mortality (HR 1.12).
Why the study?
Right ventricular systolic dysfunction is a common complication of COVID-19, but the predictive performance and association of right ventricular free wall longitudinal strain with 30-day mortality required evaluation.
Does right ventricular free wall longitudinal strain (RV-FWLS) predict 30-day mortality in patients with severe COVID-19 pneumonia?
Observational (n=116)
No
Does right ventricular free wall longitudinal strain (RV-FWLS) predict 30-day mortality in patients with severe COVID-19 pneumonia?
Hazard Ratio: 1.12 (95% CI 0.49–2.55)
Absolute Event Rate: 21% vs 19%
p-value: p=0.78
In patients with severe COVID-19 pneumonia, right ventricular free wall longitudinal strain (RV-FWLS) and conventional RV parameters failed to predict 30-day mortality.
RV-FWLS was not associated with 30-day mortality; leaves open the prognostic role of RV strain in severe COVID-19.
Introduction: Right ventricular (RV) systolic dysfunction (RVsD) is a common complication of coronavirus infection 2019 disease (COVID-19). The right ventricular free wall longitudinal strain parameter (RV-FWLS) is a powerful predictor of mortality. We explored the performance of RVsD parameters for predicting 30-day mortality and the association between RV-FWLS and 30-day mortality. Methods: COVID-19 patients hospitalized at Amiens University Hospital in the critical care unit with transthoracic echocardiography were included. We measured tricuspid annular plane systolic excursion (TAPSE), the RV S’ wave, RV fractional area change (RV-FAC), and RV-FWLS. The diagnostic performance of RVsD parameters as predictors for 30-day mortality was evaluated by the area under the receiver operating characteristic (ROC) curve (AUC). RVsD was defined by an RV-FWLS < 21% to explore the association between RVsD and 30-day mortality. Results: Of the 116 patients included, 20% (n = 23/116) died and 47 had a RVsD. ROC curve analysis showed that RV-FWLS failed to predict 30-day mortality, as did conventional RV parameters (all p > 0.05). TAPSE (21 (19−26) mm vs. 24 (21−27) mm; p = 0.024) and RV-FAC (40 (35−47)% vs. 47 (41−55)%; p = 0.006) were lowered in the RVsD group. In Cox analysis, RVsD was not associated with 30-day mortality (hazard ratio = 1.12, CI 95% (0.49−2.55), p = 0.78). Conclusion: In severe COVID-19 pneumonia, RV-FWLS was not associated with 30-day mortality.
No takes yet. Share an insight, caveat, or question.
Beyls et al. (2022) conducted an observational in Severe COVID-19 pneumonia (n=116). Right ventricular systolic dysfunction (RV-FWLS < 21%) vs. No right ventricular systolic dysfunction (RV-FWLS ≥ 21%) was evaluated on 30-day mortality (HR 1.12, 95% CI 0.49-2.55, p=0.78). In patients with severe COVID-19 pneumonia, right ventricular systolic dysfunction defined by an RV-FWLS < 21% was not associated with 30-day mortality (HR 1.12).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: